The principal investigators of the REDUCE (Randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the Combo dual-therapy stent) trial have announced the enrolment of the first patient at Isala Hospital, Zwolle, the Netherlands.
The local principal investigator and treating physician, E Kedhi, reports that the 81-year-old female patient was successfully treated with the Combo stent. The patient consented enrolment in the trial, and was randomised to one of the two treatment arms involving either three months or 12 months of dual antiplatelet therapy.
It is the aim of the current study to demonstrate non-inferiority of a strategy of short-term dual antiplatelet therapy (three months) as compared to standard 12-month dual antiplatelet therapy in acute coronary syndrome patients treated with the Combo stent.
The REDUCE study is a prospective, multicentre, randomised, investigator-initiated study designed to enrol 1,500 patients with acute coronary syndrome who will receive a Combo dual therapy stent. Patients will be randomised 1:1 to either short-term (three months) or standard (12 months) dual antiplatelet therapy within the hospitalisation period (before discharge in case additional revascularisation is deemed necessary and performed during hospitalisation). Clinical follow-ups are scheduled at three, six, 12 and 24 months. Thirty hospitals in Asia and Europe will participate in the study.
The primary endpoint of the study is composite of all-cause mortality, myocardial infarction, stent thrombosis, stroke, target vessel revascularisation or bleeding (BARC II, III, V) at 12 months.